Amylyx Pharmaceuticals, Inc. (AMLX) vs Enliven Therapeutics, Inc. (ELVN)
A side-by-side comparison of Amylyx Pharmaceuticals, Inc. and Enliven Therapeutics, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
AMLX
Amylyx Pharmaceuticals, Inc.
$28.57HealthcareDelayed quote: Oct 6, 2026, 9:30 AM EDT
ELVN
Enliven Therapeutics, Inc.
$45.47HealthcareDelayed quote: Oct 5, 2026, 4:00 PM EDT
Total return — AMLX vs ELVN
growth of $100 · dividends reinvested · last 5yAMLX +53.7% (+9.0%/yr)ELVN +428.7% (+39.5%/yr)ELVN compounded faster over this window
AMLX ELVN
AMLX vs ELVN: by the numbers
- •ELVN is the larger company ($3.25B vs $3.18B market cap).
Metrics side by side
Valuation
| Metric | AMLX | ELVN |
|---|---|---|
| P/B ratio | 13.28 | 3.63 |
Profitability
| Metric | AMLX | ELVN |
|---|---|---|
| Gross margin | 0.00% | 0.00% |
| Operating margin | 0.00% | 0.00% |
| Net margin | 0.00% | 0.00% |
| ROE | -63.59% | -11.83% |
| ROIC | -66.60% | -13.88% |
Growth (annualized)
| Metric | AMLX | ELVN |
|---|---|---|
| Total return CAGR (5Y) | N/A | 24.57% |
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.